Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment—Analyses from the German clinical RCC-Registry
Urologic Oncology: Seminars and Original Investigations Aug 23, 2018
Goebell PJ, et al. - In patients being treated for metastatic renal cell carcinoma (mRCC) in Germany, authors evaluated the prognostic impact of body mass index (BMI). As per data, high BMI was significantly and independently associated with longer OS in a prospective German cohort of mRCC routine patients starting first-line systemic treatment. They noted an independent association of Memorial Sloan Kettering Cancer Center risk factors with shorter OS.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins